| Abstrakt: |
A recent study from Sirius University of Science and Technology in Sochi, Russia, explores the use of oncolytic vesicular stomatitis virus (VSV) in cancer gene therapy. The research highlights the potential of VSV due to its ability to infect and destroy cancer cells while stimulating an immune response. The study discusses various strategies for optimizing VSV's oncolytic properties, including gene modifications and combination therapies with other anticancer drugs. For more information, the full report can be accessed in Frontiers in Bioscience-Landmark, 2024,29(11). [Extracted from the article] |
